Abstract
The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Current Computer-Aided Drug Design
Title:Structure-Based Development of Antagonists for Chemokine Receptor CXCR4
Volume: 9 Issue: 1
Author(s): Chongqian Zhang, Tingjun Hou, Zhiwei Feng and Youyong Li
Affiliation:
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Abstract: The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Export Options
About this article
Cite this article as:
Zhang Chongqian, Hou Tingjun, Feng Zhiwei and Li Youyong, Structure-Based Development of Antagonists for Chemokine Receptor CXCR4, Current Computer-Aided Drug Design 2013; 9 (1) . https://dx.doi.org/10.2174/1573409911309010006
DOI https://dx.doi.org/10.2174/1573409911309010006 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design Leptin and Inflammation
Current Immunology Reviews (Discontinued) Adenoviral Gene Delivery for HIV-1 Vaccination
Current Gene Therapy Cartilage Tissue Engineering: Towards a Biomaterial-Assisted Mesenchymal Stem Cell Therapy
Current Stem Cell Research & Therapy The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry The Effect of Levothyroxine in Comparison with Placebo on Serum Osteocalcin Levels in Patients with Subclinical Hypothyroidism
Current Drug Safety ETS Proteins and MMPs: Partners in Invasion and Metastasis
Medicinal Chemistry Reviews - Online (Discontinued) Current Research on Protein-Protein Interactions Among Auxin-Signaling Factors in Regulation of Plant Growth and Development
Current Pharmaceutical Biotechnology Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Targeting Bcl-2 in CLL
Current Medicinal Chemistry Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Synthesis and Screening of N-Alkyl Hydroxamates for Inhibition of Cancer Cell Proliferation
Combinatorial Chemistry & High Throughput Screening Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design